The abstract is read at the publisher; the summary is JClub's.
α-synuclein transgenic mouse models carrying familial-PD-linked SNCA mutations develop intraneuronal lesions rich in αS phospho-serine 129, matching a key human PD histopathological signature.
- Why it matters: Disease-modifying PD therapies need models that reproduce core motor symptoms and, in some cases, cognitive pathology in neocortical areas.
- What they did: The review synthesizes advances from toxin-based rodent models to SNCA mutation mice and newer strains with strategic amplifications of familial αS mutants, emphasizing their use for drug efficacy and target engagement testing.
- The result: Strategic amplification models produce more pronounced neurodegeneration and progressive phenotypes, supporting their use to probe disease mechanisms and guide translational drug development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.